Hwang Insang, Lim Donghoon, Jeong Young Beom, Park Seung Chol, Noh Jun Hwa, Kwon Dong Deuk, Kang Taek Won
Department of Urology, Chonnam National University Medical School, Gwangju, Korea.
Asian J Androl. 2015 Sep-Oct;17(5):811-4. doi: 10.4103/1008-682X.143751.
Only 54% of prostate cancer cases in Korea are localized compared with 82% of cases in the US. Furthermore, half of Korean patients are upgraded after radical prostatectomy (41.6%-50.6%). We investigated the risk factors for upgrading and/or upstaging of low-risk prostate cancer after radical prostatectomy. We retrospectively reviewed the medical records of 1159 patients who underwent radical prostatectomy at five hospitals in Honam Province. Preoperative data on standard clinicopathological parameters were collected. The radical prostatectomy specimens were graded and staged and we defined a "worsening prognosis" as a Gleason score ≥ 7 or upstaging to ≥ pT3. Multivariate logistic regression models were used to assess factors associated with postoperative pathological upstaging. Among the 1159 patients, 324 were classified into the clinically low-risk group, and 154 (47.5%) patients were either upgraded or upstaged. The multivariable analysis revealed that the preoperative serum prostate-specific antigen level (odds ratio [OR], 1.131; 95% confidence interval [CI], 1.007-1.271; P= 0.037), percent positive biopsy core (OR: 1.018; 95% CI: 1.002-1.035; P= 0.032), and small prostate volume (≤30 ml) (OR: 2.280; 95% CI: 1.351-3.848; P= 0.002) were predictive of a worsening prognosis. Overall, 47.5% of patients with low-risk disease were upstaged postoperatively. The current risk stratification criteria may be too relaxed for our study cohort.
在韩国,只有54%的前列腺癌病例处于局部阶段,而美国这一比例为82%。此外,韩国一半的患者在根治性前列腺切除术后病理分级上升(41.6%-50.6%)。我们调查了根治性前列腺切除术后低风险前列腺癌分级上升和/或分期上升的危险因素。我们回顾性分析了全罗南道五家医院1159例行根治性前列腺切除术患者的病历。收集了标准临床病理参数的术前数据。对根治性前列腺切除术标本进行分级和分期,我们将“预后恶化”定义为Gleason评分≥7或分期上升至≥pT3。采用多变量逻辑回归模型评估与术后病理分期上升相关的因素。在1159例患者中,324例被归类为临床低风险组,154例(47.5%)患者出现分级上升或分期上升。多变量分析显示,术前血清前列腺特异性抗原水平(比值比[OR],1.131;95%置信区间[CI],1.007-1.271;P=0.037)、活检阳性核心百分比(OR:1.018;95%CI:1.002-1.035;P=0.032)和前列腺体积小(≤30ml)(OR:2.280;95%CI:1.351-3.848;P=0.002)可预测预后恶化。总体而言,47.5%的低风险疾病患者术后分期上升。对于我们的研究队列,目前的风险分层标准可能过于宽松。